Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients

被引:53
|
作者
Chen, Qingyong [1 ]
Fei, Jun [1 ]
Wu, Lijun [1 ]
Jiang, Zhongyong [1 ]
Wu, Yuquan [1 ]
Zheng, Yun [1 ]
Lu, Guohua [2 ]
机构
[1] 117th Hosp PLA, Dept Resp Dis, Hangzhou 310013, Zhejiang, Peoples R China
[2] Zhejiang Univ, Dept Resp Dis, Affiliated Hosp 1, Coll Med, Hangzhou 310004, Zhejiang, Peoples R China
关键词
cathepsin B; cathepsin L; cysteine C; urokinase plasminogen activator; urokinase plasminogen activator receptor; lung cancer; progonosis; sera; INHIBITORS STEFIN-A; PROGNOSTIC-SIGNIFICANCE; PULMONARY ADENOCARCINOMAS; CLINICAL-SIGNIFICANCE; CYSTEINE PROTEINASES; COLORECTAL-CANCER; EXPRESSION; METASTASIS; PROTEASES; PROGRESSION;
D O I
10.3892/ol.2011.302
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The present study aimed to determine the levels of cathepsin B (cath B), cathepsin L (cath L), cystatin C, urokinase plasminogen activator (u-PA) and urokinase plasminogen activator receptor (u-PAR) in the sera of patients with lung cancer compared to healthy controls using ELISA. Concomitantly, the relationship between the components and clinicopathological prognosis was analyzed. The study included 30 healthy volunteers and 105 lung cancer patients. Blood samples were collected and cath B, cath L, cystatin C, u-PA and u-PAR measurements were made using ELISA. Results showed that the levels of cath B, cath L, cystatin C, u-PA and u-PAR were significantly higher in the patient group compared to the healthy controls. The significance was marked for cath B and mild for u-PAR in correlation with lymph node metastasis. There was no significance for other parameters. Notably, patients with a combination of high cystatin C and high cath B levels had significantly lower survival probability as compared to those with cystatin C(+)/cath B(-) or with cystatin C(-)/cath B(-), Similarly, patients with a combination of high u-PA and u-PAR experienced significantly shorter survival., Furthermore, the univariate analysis revealed that cath B, u-PAR, lymph node metastases, stage and grade were related to survival. However, findings of the multivariate Cox analysis indicated that the sera levels of cath B, u-PAR and lymph node metastases may serve as independent prognostic variables in patients with lung cancer.
引用
收藏
页码:693 / 699
页数:7
相关论文
共 50 条
  • [31] Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients
    Levicar, N
    Kos, J
    Blejec, A
    Golouh, R
    Vrhovec, I
    Frkovic-Grazio, S
    Lah, TT
    CANCER DETECTION AND PREVENTION, 2002, 26 (01): : 42 - 49
  • [32] The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer
    Brünner, N
    Nielsen, HJ
    Hamers, M
    Christensen, IJ
    Thorlacius-Ussing, O
    Stephens, RW
    APMIS, 1999, 107 (01) : 160 - 167
  • [33] Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and-2 in hepatocellular carcinoma
    Zhou, L
    Hayashi, Y
    Itoh, T
    Wang, WP
    Rui, JA
    Itoh, H
    PATHOLOGY INTERNATIONAL, 2000, 50 (05) : 392 - 397
  • [34] Tristetraprolin Inhibits the Growth of Human Glioma Cells through Downregulation of Urokinase Plasminogen Activator/Urokinase Plasminogen Activator Receptor mRNAs
    Ryu, Jinhyun
    Yoon, Nal Ae
    Lee, Yeon Kyung
    Jeong, Joo Yeon
    Kang, Seokmin
    Seong, Hyemin
    Choi, Jungil
    Park, Nammi
    Kim, Nayoung
    Cho, Wha Ja
    Paek, Sun Ha
    Cho, Gyeong Jae
    Choi, Wan Sung
    Park, Jae-Yong
    Park, Jeong Woo
    Kang, Sang Soo
    MOLECULES AND CELLS, 2015, 38 (02) : 156 - 162
  • [35] Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients
    Chung, HC
    Rha, SY
    Park, JO
    Yoo, NC
    Kim, JH
    Roh, JK
    Min, JS
    Lee, KS
    Kim, BS
    Kim, JJ
    BREAST CANCER RESEARCH AND TREATMENT, 1998, 49 (01) : 41 - 50
  • [36] Urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitor-1 in small cell carcinoma of the lung and non-small cell carcinoma of the lung
    Wajima, T
    VonHoff, DD
    THROMBOSIS AND HAEMOSTASIS, 1997, : P2264 - P2264
  • [37] Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients
    Hyun Cheol Chung
    Sun Young Rha
    Joon Oh Park
    Nae Choon Yoo
    Joo Hang Kim
    Jae Kyung Roh
    Jin Sik Min
    Kyong Sik Lee
    Byung Soo Kim
    Jin Ju Kim
    Breast Cancer Research and Treatment, 1998, 49 : 41 - 50
  • [38] REGULATION OF THE UROKINASE RECEPTOR BY ITS PLASMINOGEN-ACTIVATOR
    HOLLAS, W
    BOYD, D
    THROMBOSIS AND HAEMOSTASIS, 1991, 66 (06) : 678 - 683
  • [39] Intermolecular contact regions in urokinase plasminogen activator receptor
    Liang, OD
    Bdeir, K
    Matz, RL
    Chavakis, T
    Preissner, KT
    JOURNAL OF BIOCHEMISTRY, 2003, 134 (05): : 661 - 666
  • [40] The role of the Urokinase Plasminogen Activator Receptor in severe asthma
    Moseley, C.
    Rankin, G.
    Sayersw, I.
    Howarth, P. H.
    Warner, J. A.
    Holloway, J. W.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2011, 41 (12): : 1828 - 1829